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Background: Position intervention has been shown to improve oxygenation, but its role in non-invasively ven-
tilated patients with severe COVID-19 has not been assessed. The objective of this study was to investigate the
efficacy of early position intervention on non-invasively ventilated patients with severe COVID-19.
Methods: This was a single-center, prospective observational study in consecutive patients with severe COVID-
19 managed in a provisional ICU at Renmin Hospital of Wuhan University from 31 January to 15 February 2020.
Patients with chest CT showing exudation or consolidation in bilateral peripheral and posterior parts of the
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lungs were included. Early position intervention (prone or lateral) was commenced for > 4 hours daily for 10
days in these patients, while others received standard care.
Results: The baseline parameters were comparable between the position intervention group (n = 17) and the
standard care group (n = 35). Position intervention was well-tolerated and increased cumulative adjusted mean
difference of SpO2/FiO2 (409, 95% CI 86 to 733) and ROX index (26, 95% CI 9 to 43) with decreased Borg scale (−9,
95 CI −15 to −3) during the first 7 days. It also facilitated absorption of lung lesions and reduced the proportion
of patients with high National Early Warning Score 2 (≥ 7) on days 7 and 14, with a trend toward faster clinical
improvement. Virus shedding and length of hospital stay were comparable between the two groups.
Conclusions: This study provides the first evidence for improved oxygenation and lung lesion absorption using
early position intervention in non-invasively ventilated patients with severe COVID-19, and warrants further
randomized trials.
Introduction
In December 2019 in Wuhan, Central China, there was an
outbreak of coronavirus disease 2019 (COVID-19), charac-
terized by atypical pneumonia.1 This has caused a global
pandemic with increasing incidence, mortality, med-
ical resource consumption, and social-economic bur-
dens. The full spectrum of COVID-19 ranges from mild,
self-limiting respiratory tract illness to severe progres-
sive pneumonia, predominately manifesting as acute
respiratory distress syndrome (ARDS) requiring admis-
sion to the intensive care unit (ICU).2 The rate of inva-
sive mechanical ventilation and mortality of patients
with severe COVID-19 remains high, partially attributed
to delayed admission and intervention during the out-
break.3,4 Despite several endeavors with randomized,
placebo-controlled trials of lopinavir-ritonavir5 and com-
passionate use of remdesivir,6 chloroquine,7 and conva-
lescent plasma,8 to date there is no approved pharmaco-
logical treatment with definite efficacy for this devastat-
ing disease.
Prone positioning has been shown to improve oxy-
genation and reduce complications and mortality in
patients with moderate-to-severe ARDS with invasive
mechanical ventilation.9,10 Likewise, lateral position-
ing has been associated with improved pulmonary gas
exchange and drainage of secretions in critically ill
patients, albeit the efficacy was inconclusive.11 The lat-
est guidance issued by the National Health Commis-
sion (NHC) of China and the World Health Organiza-
tion (WHO) for management of COVID-19 recommended
only that prone positioning could be applied in criti-
cally ill patients who were under invasive mechanical
ventilation. A recent preliminary study of 12 patients
critically ill with COVID-19 showed that position inter-
vention was associated with improved oxygenation
and lung recruitability.12 However, the effects of posi-
tion intervention have not been assessed in awake
patients with severe COVID-19 without intubation at
admission.
The objective of this study was to investigate the
impact of early prone or lateral positioning on oxygena-
tion improvement, lung lesion absorption, and other
clinical outcomes in awake patients with severe COVID-
19.
Methods
Study design and patients
This prospective, observational cohort study, was
designed, conducted, and reported according to
Strengthening the Reporting of Observational Stud-
ies in Epidemiology (STROBE) guidelines.13 Consecutive
patients with COVID-19 admitted to provisional ICUs
in Renmin Hospital of Wuhan University (between 31
January and 15 February 2020) were scrutinized for
inclusion. This study sought to compare the clinical
outcomes between patients who received early posi-
tion intervention and those who had standard care
only. The study protocol was reviewed and approved
by the Institutional Review Board of Renmin Hospi-
tal of Wuhan University (No. WDRY2020-K068). On a
separate note, studies in China comparing patients in
ICU with non-ICU or patients with severe disease with
non-severe were manually searched (by W.C. to 20 April
2020) to understand the baseline characteristics of these
patients.
Diagnosis of COVID-19 was defined as the presence
of severe acute respiratory syndrome coronavirus 2
before admission, determined by a reverse transcription-
polymerase chain reaction method as per NHC of China14
and WHO15 standards. Patients were included in this
study if they met the following criteria: classified as
severe category of COVID-19, manifesting as dyspnea
with respiratory rate (RR) ≥ 30 breaths/min, pulse oxy-
gen saturation ≤ 93% at rest, or partial pressure of arte-
rial oxygen (PaO2) to fraction of inspired oxygen (FiO2)
ratio ≤ 300 mmHg14; with chest computerized tomo-
graphic (CT) images showing exudation or consolidation
mainly in the bilateral peripheral and posterior parts of
the lungs.
Patients were excluded if they were aged < 18 or > 80
years old; were pregnant; were critically ill (invasive
mechanical ventilation, severe cardiac failure, or hemo-
dynamically unstable)14; contraindicated to the prone or
lateral position (i.e. a history of the vertebral disease); or
were unable to cooperate.
Three attending physicians independently analyzed
eligibility of patients for recruitment (Z.L., J.L., and T.W.).
If there was a disagreement, the final decision was made
by the medical team leader (D.L.).
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Interventions and measurements
All patients received standard care according to the
interim guidance version 4 issued by the NHC of China.14
According to whether or not they received position inter-
vention, the patients were divided into two groups:
1. Standard care group: standard care comprised sup-
plemental oxygen and ventilation, antivirals (rib-
avirin or arbidor), antibiotics, anticoagulants, and
glucocorticoids, as necessary, based on the clinical
condition of the patients. In this group, no position
intervention was introduced.
2. Position intervention group: prone positioning was
superimposed on the standard care at the doc-
tors’ discretion without pre-defined selection crite-
ria. Where prone positioning was not tolerated by a
patient, lateral positioning was implemented as an
alternative. Each patient was placed in position for at
least 4 hours per day for 10 days. The exact position
placement was performed and managed by an expe-
rienced respiratory therapist and a physician, and all
patients were evaluated every morning.
Vital signs, oxygen saturation measured by pulse
oximetry (SpO2), FiO2, and Borg scale (a 0–10 category
scale verbal description for severity of dyspnea)16 were
recorded between 9 and 11 am daily for at least 7 days. To
determine illness severity, the Pneumonia Severity Index
(PSI)17 was estimated within 24 hours of admission. The
risk of clinical deterioration were assessed with three
levels of National Early Warning Score 2 (NEWS2): Low
score, an aggregate of 1–4 (or a score of 3 in any one
parameter); Medium score, an aggregate of 5 or 6, indica-
tive of potential severe acute clinical deterioration and
the need for an urgent clinical response; High score, an
aggregate score of ≥ 7.18 NEWS2 was assessed at enroll-
ment, on days 7 and 14 thereafter or before decreased.
In addition to the chest CT scan prior to admission,
all patients in this study underwent follow-up CT exam-
inations on day 10 after enrollment. The imaging results
were interpreted by two attending radiologists who were
unaware of the study design. The principle of discharge
was based on relief of symptoms, obvious absorption of
inflammation in chest CT, abatement of fever, and viral
clearance with throat swabs two consecutive times more
than 24 hours apart.
Data collection
The data collection process followed quality assurance
and standard operating procedures developed by senior
authors (W.L., J.L., F.L., and D.L.). Two researchers (Z.L.
and J.L.) independently started data collection at enroll-
ment from electronic medical records independently
using pre-defined pro forma. Data quality were checked
by a third researcher (T.W.). These data contained epi-
demiological, virologic, clinical, laboratory, microbiologi-
cal, radiological characteristics, disease severity indices,
respiratory support method, pharmacological treatment,
and other management details.
Outcome and safety measures
The primary outcome was oxygenation improvement,
determined by cumulative adjusted mean difference of
SpO2/FiO2 (serving as oxygen saturation index), Res-
piratory rate-Oxygenation (ROX) index, and Borg scale
between position intervention and standard care.
Secondary outcomes were lung lesion absorption,
NEWS2, time to clinical improvement, rate of intubation
avoidance, death, time to virus shredding, length of hos-
pital stay, and adverse events. The lung lesion absorp-
tion was described as changes in chest CT manifesta-
tions after treatment as contrast to admission imaging
findings. A semi-quantitative scoring system was used
to quantitatively estimate the pulmonary involvement of
all abnormalities on the basis of the area involved.19 Each
of the five lung lobes was visually scored from 0 to 5 as
per a previous study: 0, no involvement; 1, < 5% involve-
ment; 2, 25% involvement; 3, 26–49% involvement; 4, 50–
75% involvement; 5, > 75% involvement. The total CT
score was the sum of the individual lobar scores and
ranged from 0 (no involvement) to 25 (maximum involve-
ment).20 The changes were stratified into obvious absorp-
tion (absorption proportion > 30%) and stable or deterio-
ration (absorption proportion ≤ 30%, without absorption
or lesion enlargement).
The time to clinical improvement was defined as the
time from enrollment to an improvement by 2 points on
a seven-category ordinal scale or live discharge from the
hospital, whichever came first.21 Adverse events for posi-
tion intervention included hemodynamic instability and
pressure sores.9,22
Statistical analysis
Continuous variables are presented as mean (SD) or
median (IQR), compared by Mann-Whitney U test. Cat-
egorical variables are expressed as frequency (percent-
age), compared by Chi-square or Fisher’s exact test as
appropriate. Logistic regression models were used to
generate propensity scores that estimated the odds of
receiving position intervention versus standard care,
covariates are age, gender, and heart rate. Adjustment
for differences in characteristics on admission was per-
formed using inverse probability of treatment weighting
(IPTW) models, to assess the effect of position interven-
tion on association of oxygenation improvement param-
eters demonstrated as forest plots. The time to clini-
cal improvement was assessed when all patients had
reached day 30 from enrollment. Data were censored
if patients failed to reach clinical improvement at day
30 or decreased before. Survival analysis was done by
Kaplan-Meier estimation (Log-rank test). Intention-to-
treat analysis was additionally performed to verify our
results.
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Figure 1. Flow chart of patient inclusion.
Statistical analysis was performed using the R statis-
tical computing environment (version 3.63). A two-sided
P value of 0.05 or less was considered to be statistically
significant.
Results
Characteristics and treatments of included
patients
The patient selection process is described in Fig. 1. A
total of 197 consecutive patients with confirmed diag-
nosis of COVID-19 was screened for inclusion during
the study period. Of these, 142 were considered ineligi-
ble for various reasons. The remaining 55 patients with
severe disease were included, of whom 20 received posi-
tion intervention and 35 had standard care only. Three
patients in the position intervention group dropped out
because of noncompliance with the procedures. Base-
line characteristics of position intervention (n = 17) vs.
standard care (n = 35) are compared and summarized
in Table 1. The mean age of patients was 62 (SD 12)
years, and 32 (62%) were male. Thirty-three patients
(64%) had comorbid chronic diseases, including hyper-
tension (33%), diabetes (21%), coronary heart disease
(14%), chronic obstructive pulmonary disease (12%), hep-
atitis B (4%), pulmonary embolism (2%), hypothyroidism
(2%), cerebral ischemic stroke (2%), and malignancy
(2%). The median time from symptom onset to hospi-
tal admission was 10 (IQR 7–14) days. At presentation,
the means for respiratory rate, PaO2/FiO2, PSI were 25
(SD 5), 133 (SD 58), and 99 (SD 20), respectively, and
the median for NEWS2 was 8 (IQR 7–9); the medians
of lymphocytes (0.67, IQR 0.49–0.93), lactate dehydroge-
nase (375, IQR 306–479), C-reactive protein (73, IQR 46–
120), and D-dimer (1.9, IQR 1.18–4.18) were out of normal
range. Chest CT revealed that the predominant pattern of
temporal abnormalities was diffuse ground-glass opacity
with mainly bilateral and subpleural distributions. These
findings are similar to clinical profiles of patients with
severe COVID in China, as reported in the literature (Sup-
plementary Tables E1–3).
Prone or lateral positioning in COVID-19 5







(n = 35) P value
Demographics
Age, yr, mean (SD) 62 ± 12 60 ± 12 64 ± 12 0.265
Age > 60 yr, n (%) 35 (67.3) 10 (58.8) 25 (71.4) 0.363
Gender, male, n (%) 32 (61.5) 11 (64.7) 21 (60.0) 0.744
Overall comorbidity, n (%) 33 (63.5) 10 (58.8) 23 (65.7) 0.628
Hypertension, n (%) 17 (32.7) 7 (41.2) 10 (28.6) 0.363
Diabetes, n (%) 11 (21.2) 4 (23.5) 7 (20.0) 1.000
Coronary heart disease, n (%) 7 (13.5) 3 (17.6) 4 (11.4) 0.855
COPD, n (%) 6 (11.5) 3 (17.6) 3 (8.6) 0.618
Time to admission, d, median (IQR) 10 (7–14) 10 (7–13) 10 (7–15) 0.448
Oxygenation status and severity
Respiratory rate, breaths/min, mean
(SD)
25 ± 5 23 ± 4 26 ± 5 0.057
< 25—n (%) 27 (51.9) 11 (64.7) 16 (45.7) 0.199
≥ 25—n (%) 25 (48.1) 6 (35.3) 19 (54.3)
PaO2/FiO2, mmHg, mean (SD) 133 ± 58 142 ± 54 128 ± 60 0.426
≥ 200 to < 300—n (%) 9 (17.3) 3 (17.6) 6 (17.1) 1.000
≥ 100 to < 200—n (%) 27 (52.0) 9 (53.0) 18 (51.4)
< 100—n (%) 16 (30.8) 5 (29.4) 11 (31.4)
PSI, mean (SD) 99 ± 20 101 ± 25 98 ± 17 0.582
≤ 90—n (%) 15 (28.8) 6 (35.3) 9 (25.7) 0.501
91–130—n (%) 35 (67.3) 9 (53.0) 26 (74.3)
> 130—n (%) 2 (3.8) 2 (11.8) 0
NEWS2, median (IQR) 8 (7–9) 9 (8–10) 8 (7–9) 0.317
1–4—n (%) 0 0 0 0.161
5–6—n (%) 6 (11.5) 0 6 (17.1)
≥ 7—n (%) 46 (88.5) 17 (100.0) 29 (82.9)
Laboratory indices
Hemoglobin, g/L, median (IQR) 127 (116–138) 130 (120–137) 127 (110–139) 0.232
< 120—n (%) 16 (30.8) 4 (23.5) 12 (34.3) 0.43
≥ 120—n (%) 36 (69.2) 13 (76.5) 23 (65.7)
WBC count, × 109/L, median (IQR) 7.08 (5.75–10.31) 7.18 (5.65–9.61) 7.04 (5.65–11.23) 0.728
4–10—n (%) 37 (71.2) 13 (76.5) 24 (68.6) 0.554
< 4—n (%) 2 (3.8) 1 (5.9) 1 (2.9)
> 10—n (%) 13 (25.0) 3 (17.6) 10 (28.6)
Lymphocyte count, × 109/L, median
(IQR)
0.67 (0.49–0.93) 0.62 (0.51–0.79) 0.68 (0.48–0.95) 0.903
≥ 1.0—n (%) 9 (17.3) 2 (11.8) 7 (20.0) 0.730
< 1.0—n (%) 43 (82.7) 15 (88.2) 28 (80.0)
Platelet count, × 109/L, median (IQR) 228 (172–290) 191 (165–268) 251 (167–313) 0.814
≥100—n (%) 49 (94.2) 15 (88.2) 34 (97.1) 0.246
<100—n (%) 3 (5.8) 2 (11.8) 1 (2.9)
ALT, U/L, median (IQR) 36 (23–61) 28.5 (22.25–43) 45 (23–65.75) 0.728
≤ 40—n (%) 29 (55.8) 12 (70.6) 17 (48.6) 0.134
> 40—n (%) 23 (44.2) 5 (29.4) 18 (51.4)
AST, U/L, median (IQR) 33 (26–46) 30 (23–41) 37 (30–48) 0.397
≤ 50—n (%) 43 (82.7) 15 (88.2) 28 (80.0) 0.730
> 50—n (%) 9 (17.3) 2 (11.8) 7 (20.0)
Creatine, μmol/L, median (IQR) 64 (50–75) 67(52–85) 63 (48–71) 0.336
≤ 133—n (%) 49 (94.2) 16 (94.1) 33 (94.3) 1.000
> 133—n (%) 3 (5.8) 1 (5.9) 2 (5.7)
LDH, U/L, median (IQR) 375 (306–479) 412 (310–478) 366 (302–522) 0.250
≤ 245—n (%) 4 (7.7) 1 (5.9) 3 (8.6) 1.000
> 245—n (%) 48 (92.3) 16 (94.1) 32 (91.4)
CK-MB, ng/L, median (IQR) 1.18 (0.79–2.01) 0.91 (0.66–1.98) 1.35 (0.94–2.13) 0.499
≤ 5—n (%) 50 (96.2) 15 (88.2) 35 (100.0) 0.103
> 5—n (%) 2 (3.8) 2 (11.8) 0
BNP, pg/L, median (IQR) 323 (204–589) 303 (188–457) 358 (204–607) 0.693
≤ 450—n (%) 24 (46.2) 3 (17.6) 21 (60.0) 0.004
> 450—n (%) 28 (53.8) 14 (82.4) 14 (40.0)








(n = 35) P value
CRP, mg/L, median (IQR) 73 (46–120) 73 (41–117) 73 (47–121) 0.976
≤ 5—n (%) 2 (3.8) 1 (5.9) 1 (2.9) 1.000
> 5—n (%) 50 (96.2) 16 (94.1) 34 (97.1)
PCT, ng/mL, median (IQR) 0.09 (0.05–0.23) 0.09 (0.07–0.23) 0.10 (0.05–0.24) 0.435
< 0.1—n (%) 28 (53.8) 11 (64.7) 17 (48.6) 0.274
≥ 0.1—n (%) 24 (46.2) 6 (35.3) 18 (51.4)
TNI, ng/L, median (IQR) 0.01 (0.01–0.01) 0.01 (0.01–0.02) 0.01 (0.01–0.01) 0.682
≤ 0.04—n (%) 51 (98.1) 17 (100.0) 34 (97.1) 1.000
> 0.04—n (%) 1 (1.9) 0 1 (2.9)
PT, second, median (IQR) 12.3 (11.7–12.8) 12.2 (11.65–12.85) 12.3 (11.7–12.8) 0.908
9–13—n (%) 45 (86.5) 14 (82.4) 31 (88.6) 0.855
≥ 13—n (%) 7 (13.5) 3 (17.6) 4 (11.4)
D-dimer, mg/L, median (IQR) 1.9 (1.18–4.18) 1.46 (0.86–3.38) 2.35 (1.21–5.05) 0.214
≤ 0.55—n (%) 3 (5.8) 1 (5.9) 2 (5.7) 1.000
> 0.55—n (%) 49 (94.2) 16 (94.1) 33 (94.3)
COPD = chronic obstructive pulmonary disease; PaO2/FiO2 = partial pressure of arterial oxygen to fraction of inspired oxygen ratio; PSI = Pneumonia Severity Index;
NEWS2 = National Early Warning Score 2; SBP = systolic blood pressure; DBP = diastolic blood pressure; WBC = white blood cell; ALT = alanine transaminase;
AST = aspartate aminotransferase; LDH = lactate dehydrogenase; CK-MB = creatine kinase myocardial band; BNP = B-type natriuretic peptide; CRP = C-reactive
protein; PCT = procalcitonin; TNI = troponin I; PT = prothrombin time.
There were no significant differences between the
position intervention group and standard care group in
terms of baseline demographics, time to admission, oxy-
genation status, severity indices, and laboratory mark-
ers (Table 1). There were also no significant differences
for respiratory support, antivirals, antibiotics, anticoag-
ulants, and glucocorticoids (and duration) between the
two groups (Table 2).
Outcome measures
Of 17 patients receiving position intervention, 11 had
prone positioning throughout the study and six changed
to lateral positioning.
The trends of changes for SpO2/FiO2, ROX index, and
Borg scale with time grouped by position intervention
(prone or lateral) and standard care are shown in Supple-
mentary Fig. E1. Compared to the standard care group,
there was a gradual increase in both SpO2/FiO2 and
ROX index with time that was mirrored by a significant
decrease of Borg scale in the prone or lateral positioning
group. Nevertheless, no significant difference between
prone and lateral positioning groups was observed for
these parameters.
Treatment effects of position intervention on oxy-
genation improvement are expressed as mean between-
group difference (95% CI) and demonstrated by forest
plots (Fig. 2). The mean difference of SpO2/FiO2 started to
increase significantly from day 4 with a cumulative value
of 409 (95% CI 86–733) after receiving position interven-
tion for 7 days (Fig. 2A). This was accompanied by sig-
nificantly increased ROX index (Fig. 2B) and decreased
Borg scale (Fig. 2C) from day 3 with cumulative values
of 26 (95% CI 9–43) and −9 (95% CI −15 to −3), respec-
tively. All these findings are suggestive of early position
intervention effectively improving oxygenation and
reducing dyspnea as compared to standard care.
Chest imaging showed that the CT score for lung
lesions was significantly reduced in both groups (Fig. 3A),
with position intervention group: 9.9 ± 1.9, after vs.
17.2 ± 5.6, before (P < 0.001) and standard care group:
10.9 ± 2, after vs. 14 ± 6, before (P < 0.015). In corrobo-
ration with improved oxygenation, early position inter-
vention was also associated with more patients having
apparent lung lesion absorption (16/17, 94% vs. 11/35,
31%, P < 0.001; Fig. 3B and Table 2). Representative chest
CT images of a patient who underwent prone positioning
are presented in Fig. 3C.
The proportion of patients with high NEWS2 (≥ 7) in
the position intervention group was significantly lower
on days 7 (11.8% vs. 51.4%, P = 0.009) and 14 (11,8% vs.
21.2%, P = 0.007) than that in the standard care group
(Table 2). There was a trend toward shortened time to
clinical improvement in the position intervention group
over the standard care group, albeit with no statistical
significance (P = 0.138) (Fig. 4).
No significant differences were observed in rate of
intubation avoidance, virus shedding, and length of hos-
pital stay between the two groups (Table 2). No adverse
events occurred during the study.
Results for clinical outcomes were unaltered between
the two groups when intention-to-treat analysis was per-
formed (Supplementary Fig. E2 and Table E4–5).
Discussion
This was the first study to evaluate the efficacy and safety
of early use of prone or lateral positioning on awake
patients with severe COVID-19 receiving non-mechanical
ventilation. Our findings indicate that position
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Figure 2. Forest plots showing between-group mean difference of position intervention vs. standard care. (A) Pulse oximetry to fraction of
inspired oxygen (SpO2/FiO2). (B) Respiratory rate-Oxygenation (ROX) index. (C) Borg scale. Data are expressed as mean (95% CI).
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(n = 35) P value
Respiratory support during study, n (%) 0.916
Nasal cannula and mask 37 (71.2) 13 (76.5) 24 (68.6)
High flow ventilation 11 (21.2) 3 (17.6) 8 (22.9)
Non-invasive mechanical ventilation 3 (5.8) 1 (5.9) 2 (5.7)
Invasive mechanical ventilation 1 (1.9) 0 (0.0) 1 (2.9)
Treatment
Antivirals, n (%) 50 (100) 17 (100) 35 (100) -
Antibiotics, n (%) 44 (84.6) 13 (76.5) 31 (88.6) 0.469
Anticoagulants, n (%) 10 (19.2) 2 (11.8) 8 (22.9) 0.564
Glucocorticoids, n (%) 34 (65.4) 12 (70.6) 22 (62.9) 0.583
Glucocorticoid duration, d, median (IQR) 3 (0–6) 3 (0–6) 3 (0–6) 0.520
CT absorption > 30%, n (%) <0.001
No 25 (48.1) 1 (5.9) 24 (68.6)
Yes 27 (51.9) 16 (94.1) 11 (31.4)
NEWS2 (d 7), median (IQR) 6 (5–8) 5 (5–5) 6 (5–8) 0.002
1–4 10 (19.2) 6 (35.3) 4 (11.4) 0.009
5–6 22 (42.3) 9 (52.9) 13 (37.1)
≥ 7 20 (38.5) 2 (11.8) 18 (51.4)
NEWS2 (d 14), median (IQR) 4 (3–6) 3 (2–3) 5 (4–7) <0.001
1–4 31 (62.0) 15 (88.2) 16 (48.5) 0.007
5–6 10 (20.0) 0 (0) 10 (30.3)
≥ 7 9 (18.0) 2 (11.8) 7 (21.2)
Rate of intubation avoidance, n (%) 51 (98) 17 (100) 34 (97.1) 1.000
Time to clinical improvement, d, median
(IQR)
33 (27–41) 31 (25–40) 35 (28–42) 0.234
Time to virus shedding, d, median (IQR) 26 (19–33) 30 (20–36) 25 (18–31) 0.315
Length of hospital stay, d, median (IQR) 35 (28–43) 35 (27–52) 35 (28–42) 0.914
Adverse events, n (%) 0 (0) 0 (0) 0 (0)
NEWS2 = National Early Warning Score 2.
intervention significantly improved oxygenation, along
with relieving subjective dyspnea and facilitating
absorption of lung lesions shown in chest images. The
position intervention reduced the proportion of patients
with high NEWS2 on days 7 and 14, and there was a
trend toward faster time to clinical improvement, but
did not correlate with virus shedding, which may have
influence on the length of hospital stay. Hence , the time
to virus shedding and length of hospital stay showed no
difference between the two groups (P > 0.05). The prone
or lateral positioning was safely performed and well
tolerated by our patients.
The main reason for ICU admission of patients with
COVID-19 is ARDS, with an incidence of 6.2% in the
Chinese population3 and 9% in Lombardy, Italy,4 dur-
ing the pandemic period with mortalities of 51% and
26%, respectively. Our chest CT images of patients with
severe COVID-19 predominantly showed exudation and
consolidation near the dorsal distribution in the periph-
eral lung.20 These imaging findings are in accordance
with post-mortem pathological appearances of the lungs
from deceased patients with COVID-19, in that the alve-
olar septa were congested and edematous along with
serous fibrin exudate and hyaline membrane seen in
the alveolar cavity, typical signs of ARDS.14 The admis-
sion features of patients with severe COVID-19 were sim-
ilar to those who were managed in the ICU settings
in China. These patients were order and had longer
time from onset to hospital admission, more comor-
bid hypertension, diabetes, cardiovascular and chronic
lung diseases, higher platelets and D-dimer, and lower
lymphocytes compared to patients with non-severe dis-
ease who were not admitted to the ICU (Supplementary
Tables E1–3).
Many patients with severe COVID-19 will rapidly
progress to refractory hypoxia, severe ARDS, an irre-
versible stage in which invasive mechanical ventilation is
inevitable. Therefore, we believe early intervention may
protect against patients with severe COVID-19 transition-
ing to the critical stage. Prone positioning during invasive
mechanical ventilation for ARDS has been extensively
studied, and it has been reported that improved oxygena-
tion and lung recruitment and may decrease mortality.23
Nevertheless, early prone positioning is recommended
for sedated patients with a threshold PaO2/FiO2 < 150
mmHg, the feasibility and timing of its application has
never been appraised in awake patients with severe
COVID-19. In our study, we had 59% (10/17) of patients
with admission PaO2/FiO2 < 150 mmHg in the position
intervention group who had faster oxygenation improve-
ment compared with those in the standard care group
(63%, 22/35). These findings imply that early position
intervention in these patients may protect against pro-
gression to severe ARDS and help to avoid the need for
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Figure 3. Chest CT score and changes before and after treatment. (A) Chest CT score. (B) Number of patients with lung lesion absorption > 30%.
(C) Chest CT images of a 52-year-old patient with COVID-19 A: (i) Chest CT images obtained on 11 February 2020 show predominantly bilateral
posterior consolidation. (ii) Chest CT images obtained on 20 February 2020 show the absorption of consolidation after prone position treatment
from 13 February to 20 February 2020.
intubation. A recent meta-analysis showed that longer
prone positioning time (≥ 12 hours) was associated with
lower mortality in patients with moderate to severe
ARDS.9 However, as it was difficult for our patients to
hold the unusual position for 12 hours, a 4-hour position-
ing procedure was adopted. This procedure appeared to
be well tolerated by 17 out of 20 patients, even in patients
with comorbid cardiovascular and lung diseases. The
reasons for three patients dropping out were mainly sub-
jective noncompliance rather than actual intolerance or
disease severity. Patient education and encouragement
may further improve tolerability and reduce nursing
burdens, of particular benefit for scarce ICU resources
during this global pandemic.24
In this study, we used the oxygen saturation index
(SpO2/FiO2) to evaluate the oxygenation levels of
patients. SpO2/FiO2 is a reliable, non-invasive surrogate
marker for PaO2/FiO2,25,26 and is more practical for
continuous oxygenation monitoring in awake patients
with COVID-19. ROX index was calculated by SpO2/FiO2
to RR and was reported to have an additive effect on
the accuracy for discriminating between success and
failure in patients who received high-flow nasal cannula
oxygen therapy.27,28 Here we used the ROX index to
10 Ni et al.
Figure 4. Time to clinical improvement.
help assess clinical improvement or deterioration. The
Borg scale measures breathlessness with a score of
0 to 10.16 It is easy to use and added a layer of reli-
ability for the improved oxygenation determined by
SpO2/FiO2 and ROX index in the position intervention
group. The improvement in oxygenation parameters
was also simultaneously associated with accelerated
lung lesion absorption. Previous studies have inves-
tigated the mechanisms of position intervention in
improving oxygenation: gravitational influence results
in increased perfusion to the well-ventilated lung, which
could enhance the ventilation-perfusion mismatch29;
prone positioning promotes the re-expansion of the
collapsed alveoli and improves oxygenation, which is
in turn conducive to elimination of secretions.30 These
mechanisms may also explain the effect of prone posi-
tion on the clinical improvement of patients with severe
COVID-19 in our study.
Patients with early prone position intervention had a
lower NEWS2 on days 7 and 14, and appeared to have
a shortened time to clinical improvement. All the above
indicates that position intervention might reduce the
risk of COVID-19 progression. Although no significant
difference was detected in avoidance of mechanical ven-
tilation between the two groups because of small sample
sizes, none of the patients in the position intervention
group required invasive mechanical ventilation. These
results were similar to a previous study, in which it was
found that patients with moderate ARDS with an initial
SpO2 > 95% on non-invasive ventilation may benefit from
early prone positioning and avoid the need for invasive
ventilation.23
Interpreting the results of this study is limited by the
small sample size, lack of randomization, and drop-out
of patients from the intervention group. Nevertheless,
the combination of oxygenation parameters (SpO2/FiO2,
ROX, and Borg scale) were observed to be consistently
improved by the position intervention, and this was also
strongly supported by improved imaging of lung lesion
abortion. To minimize potential bias for not being ran-
domized, we set up the same protocols for daily manage-
ment and the same criteria for imaging and discharge.
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Moreover, the intention-to-treat analysis did not change
the overall results obtained.
In conclusion, this was the first study demonstrat-
ing that early prone or lateral positioning could improve
clinical manifestation and radiological features in non-
invasively ventilated patients with severe COVID-19.
Because position intervention is simple, inexpensive,
and safe, it may be adopted as a regular procedure for
the early management of patients with severe COVID-
19 without invasive ventilation. However, based on the
study limitations (small number of patients, nonran-
domized trial), a randomized controlled trial is recom-
mended to confirm this hypothesis.
Supplementary data
Supplementary data are available at Precision Clinical
Medicine online.
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